Post by babaoriley on Mar 19, 2016 0:14:58 GMT -5
I guess myself personally, I don't see why it's worth any less now than it was at 7, 11, etc. We are a year plus down the road, people that know about Afrezza and how to effectively use it love it, we are about to get out from under SNY who sandbagged the shit out of us as well as get 100% of the profits instead of 25/35%. I get it that expenses will be 100% ours but more than likely as a smaller entity MNKD can operate a hell of a lot more efficiently than the 3 ring circus SNY can as it's just too big of an organization. The bigger a company gets generally the more wasteful they are with money. And who's to say they were being honest with the expenses MNKD had to share with them?
Over the last 3 or 4 years i've purchased this from .67 cents all the way to $9 a share with a average at $3.31 per share. Maybe it's because i still have a KoolAid stain but I feel things are better now then they were 2 years ago. There is the whole cash situation but something appears to be cooking on that as nobody seems worried on the inside and high profile executives are leaving good jobs to be part of it.
Just my 2 cents. Disclaimer that i've been consistently wrong on this stock for past 3 to 4 years i've been involved with it.
Nate Pile, who recently quadrupled his position from 200,000 shares to 800,000 shares over the last several months, now rates Mannkind a strong buy under $2 and a buy under $5.
And as per Nate, without all the shorting, Mannkind should be trading at $8-$12 right now.
stocktwits.com/NatesNotes
In my view, if Afrezza succeeds (no need for wild success, like 5 billion annual sales, etc., just a mild success, say annual sales of $500 million to $1 billion within several few years, which is totally achievable), based on Afrezza alone, Mannkind will be worth $5-$10 billion, which translates to $10-$20 a share. Giving it a some discount for time value, etc., $5-$7 a share is very reasonable.
Think about it, by the time Sanofi terminated the partnership agreement, Sanofi was only able to attract 6,000 people to try out Afrezza. Give it a year, I think it is totally doable for Mannkind to attract 60,000 people to try out Afrezza using its own efforts, with the help of VDEX diabetics care and others. That alone will grow the Trx by 10 times.